Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.xinn.2020.100028 http://scihub22266oqcxt.onion/10.1016/j.xinn.2020.100028 33521761!7836536!33521761     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Innovation+(Camb) 2020 ; 1 (2): 100028 Nephropedia Template TP {{tp|p=33521761|t=2020. Patients Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation |pdf=|usr=}}{{33521761}} gab.com Text Patients Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation JO: Innovation (Camb) http://www.kidney.de/pget.php?&tw=1&pmid=33521761 #FOAvip Since the outbreak of COVID-19, many randomized controlled trials have been launched to test the efficacy of promising treatments. These trials will offer great promise for future treatment. However, a public health emergency calls for a balance between gathering sound evidence and granting therapeutic access to promising trial drugs as widely as possible. In an electronic survey, we found that 3.9% of the participants preferred to receive an unproven trial drug directly in the hypothetical scenario of mild COVID-19 infection. This percentage increased drastically to 31.1% and 54.2% in the hypothetical scenario of severe and extremely severe infection, respectively. Our survey indicates a likelihood of substantial receptivity of trial drugs among actual patients in severe conditions. From the perspective of deontological ethics, a trial can only be approved when potential benefits of the investigational treatment are presumed to outweigh risks, so compassionate or off-label use of investigational therapies merits evaluation. Twit Text FOAVip Patients Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation ????Innovation (Camb) http://www.kidney.de/pget.php?&tw=1&pmid=33521761 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33521761 #FOAvip English Wikipedia <ref>{{Cite pmid|33521761}}</ref> Patients Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation #MMPMID33521761 Li HT; Cheng ZH; Huang YY; Lv XL; Zhou YB; Dong E; Liu JM Innovation (Camb) 2020[Aug]; 1 (2): 100028 PMID33521761show ga Since the outbreak of COVID-19, many randomized controlled trials have been launched to test the efficacy of promising treatments. These trials will offer great promise for future treatment. However, a public health emergency calls for a balance between gathering sound evidence and granting therapeutic access to promising trial drugs as widely as possible. In an electronic survey, we found that 3.9% of the participants preferred to receive an unproven trial drug directly in the hypothetical scenario of mild COVID-19 infection. This percentage increased drastically to 31.1% and 54.2% in the hypothetical scenario of severe and extremely severe infection, respectively. Our survey indicates a likelihood of substantial receptivity of trial drugs among actual patients in severe conditions. From the perspective of deontological ethics, a trial can only be approved when potential benefits of the investigational treatment are presumed to outweigh risks, so compassionate or off-label use of investigational therapies merits evaluation. äPatients Attitudes to Unproven Therapies in Treating COVID-19 Merit E(epmc).pdf DeepDyve Pubget Overpricing